The Real Impact Of Drug Price Legislation On Biopharmaceutical R & D

As outcry around drug prices rages, arguments continue to surface that limiting corporate revenues via price controls will have little impact on biopharmaceutical innovation. The latest salvo comes from academics at Rutgers Law School. In an article published by STAT, the authors claim that the industry grossly overstates the impact of price controls, likening the industry to Aesop’s boy who cried wolf.